BEST3 and cancer: Further supporting this notion, Cox regression analysis across pan‐cancer datasets revealed that elevated BEST3 expression was linked to poorer prognosis, especially in LUAD, where higher expression levels corresponded to significantly worse survival outcomes (Figure S8E).